Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

Diabetes

Volumn 49, Issue 6, 2000, Pages 999-1005

  Kurtzhals, Peter ^a   Schäffer, Lauge ^a   Sørensen, Anders ^a   Kristensen, Claus ^a   Jonassen, Ib ^a   Schmid, Christoph ^b   Trüb, Thomas ^b  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN RECEPTOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; HUMAN CELL; METABOLIC REGULATION; MITOGENESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RISK BENEFIT ANALYSIS;

EID: 0342657181     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.6.999     Document Type: Article

References (49)

1. Brange J, Vølund A: Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35:307-335, 1999
2. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42:1151-1167, 1999
3. Kristensen C, Kjeldsen T, Wiberg FC, Schäffer L, Hach M, Havelund S, Bass J, Steiner DF, Andersen AS: Alanine scanning mutagenesis of insulin. J Biol Chem 272:12978-12983, 1997
4. Gammeltoft S: Insulin receptors: binding kinetics and structure-function relationship of insulin. Physiol Rev 64:1321-1378, 1984
5. Baker EN, Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DMC, Hubbard RE, Isaacs NW, Reynolds CD, Sakabe K, Sakabe N, Vijayan NM: The structure of 2Zn pig insulin crystals at 1.5 Å resolution. Philos Trans R Soc Lond B Biol Sci 319:369-456, 1988
6. Brange J, Owens DR, Kang S, Vølund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
7. DeMeyts P: The structural basis of insulin and insulin-like growth-factor-I receptor-binding and negative cooperativity, and its relevance to mitogenic versus metabolic signaling. Diabetologia 37:S135-S148, 1994
8. Drejer K: The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259-285, 1992
9. Hansen BF, Danielsen GM, Drejer K, Sørensen AR, Wiberg FC, Klein HH, Lundemose AG: Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271-279, 1996
10. Slieker LJ, Brooke GS, Dimarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL, Surface PL, Chance RE: Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 40:S54-S61, 1997
11. Kaarsholm NC, Ludvigsen S: The high resolution solution structure of the insulin monomer determined by NMR. Receptor 5:1-8, 1995
12. Reid TW, Reid WA: The labile nature of the insulin signal(s) for the stimulation of DNA synthesis in mouse lens epithelial and 3T3 cells. J Biol Chem 262:229-233, 1987
13. Markussen J, Diers I, Engesgaard A, Hansen MT, Hougaard P, Langkjaer L, Norris K, Ribel U, Sørensen AR, Sørensen E, Voigt HO: Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30. Protein Eng 1:215-223, 1987
14. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schäffer L, Vad K, Jonassen I: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-288, 1996
15. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjørn S, Gammeltoft S: Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488-1495, 1991
16. Schäffer L, Larsen UD, Linde S, Hejnaes KR, Skriver L: Characterization of the 3 i-125 iodination isomers of human insulin-like growth-factor I (igfI). Biochem Biophys Acta 1203:205-209, 1993
17. Mynarcik DC, Williams PF, Schaffer L, Yu GQ, Whittaker J: Identification of common ligand binding determinants of the insulin and insulin-like growth factor 1 receptors: insights into mechanisms of ligand binding. J Biol Chem 272:18650-18655, 1997
18. Moody AJ, Stan MA, Stan M, Gliemann J: A simple free fat cell bioassay for insulin. Horm Metab Res 6:12-16, 1974
19. Vølund A: Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models. Biometrics 34:357-365, 1978
20. Rodan SB, Wesolowski G, Ianacone J, Thiede MA, Rodan GA: Production of parathyroid hormone-like peptide in a human osteosarcoma cell line: stimulation by phorbol esters and epidermal growth factor. J Endocrinol 122:219-227, 1989
21. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J: Albumin binding and time action of acylated insulins in various species. J Pharm Sci 85:304-308, 1996
22. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J: Albumin-binding of insulins acylated with fatty-acids: characterization of the ligand protein-interaction and correlation between binding-affinity and timing of the insulin effect in-vivo. Biochem J 312:725-731, 1995
23. Gammeltoft S, Hansen BF, Dideriksen L, Lindholm A, Schäffer L, Trub T, Dayan A, Kurtzhals P: Insulin aspart: a novel rapid-acting human insulin analogue. Exp Opin Invest Drugs 8:1431-1441, 1999
24. Lammers R, Gray A, Schlessinger J, Ullrich A: Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 8:1369-1375, 1989
25. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T: Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 16:332-338, 1999
26. Brunner GA, Sendlhofer G, Wutte A, Ellmerer M, Soegaard B, Siebenhofer A, Hirschberger S, Krejs GJ, Pieber TR: Pharmacokinetic and pharmacodynamic properties of insulin analog NN304 in comparison to NPH insulin in humans (Abstract). Diabetes 48 (Suppl. 1):A102, 1999
27. Ribel U, Hougaard P, Drejer K, Sørensen AR: Equivalent in-vivo biological activity of insulin analogues and human insulin despite different in-vitro potencies. Diabetes 39:1033-1039, 1990
28. Zhang WG, Gustafson TA, Rutter WJ, Johnson JD: Positively charged sidechains in the insulin-like growth-factor-I c-regions and d-regions determine receptor-binding specificity. J Biol Chem 269:10609-10613, 1994
29. Bähr M, Kolter T, Seipke G, Eckel J: Growth promoting and metabolic activity of the human insulin analogue [Gly(A21),Arg(B31),Arg(B32)]insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265, 1997
30. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Häring HU: The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123-129, 1998
31. Siddle K, Soos MA, Field CE, Nave BT: Hybrid and atypical insulin/insulin-like growth factor I receptors. Horm Res 41:56-64, 1994
32. Soos MA, Field CE, Siddle K: Purified hybrid insulin insulin-like growth factor-I receptors bind insulin insulin-like growth factor-I, but not insulin, with high-affinity. Biochem J 290:419:426, 1993
33. Kasuya J, Paz IB, Maddux BA, Goldfine ID, Hefta SA. Fijitayamaguchi Y: Characterization of human placental insulin-like growth factor-I insulin hybrid receptors by protein microsequencing and purification. Biochemistry 32:13531-13536, 1993
34. Humbel RE: Insulin-like growth factors I and II. Eur J Biochem 190:445-462, 1990
35. Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR: Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 42:145-151, 1994
36. Kiess W, Kessler U, Schmitt S, Funk B: Growth hormone and insulin-like growth factor I: basic aspects. In Growth Hormone and Insulin-Like Growth Factor I in Human and Experimental Diabetes. Flyvbjerg A, Ørskov H, Alberti KGMM, Eds. Chichester, U.K., Wiley, 1993, p. 1-21
37. Leroith D, Baserga R, Helman L, Roberts CT: Insulin-like growth-factors and cancer. Ann Intern Med 122:54-59, 1995
38. Blakesley VA, Stannard BS, Kalebic T, Helman LJ, Leroith D: Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 152:339-344, 1997
39. Smith LEH, Shen W, Perruzzi C, Soker S, Kinose F, Xu XH, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5:1390-1395, 1999
40. Smith LEH, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276:1706-1709, 1997
41. Merimee TJ, Zapf J, Froesch ER: Insulin-like growth factor studies in diabetics with and without retinopathy. N Engl J Med 309:527-530, 1983
42. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J: Insulin-like growth factor-I acts as an angiogenic agent in rabbit cornea and retina: comparative-studies with basic fibroblast growth-factor. Diabetologia 36:282-291, 1993
43. Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA: Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 48:377-382, 1999
44. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB: Randomized placebo-controlled trial of human recombinant insulin-like-growth-factor-I plus intensive insulin therapy in adolescents with insulin-dependent diabetes-mellitus. Lancet 350:1199-1204, 1997
45. Dunger DB, Acerini CL: Does recombinant human insulin-like growth-factor-I have a role in the treatment of diabetes? Diabet Med 14:723-731, 1997
46. Kitzmiller JL, Main E, Ward B, Theiss T, Peterson DL: Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 22:874-876, 1999
47. Markussen J: Human Insulin by Tryptic Transpeptidation of Porvine Insulin and Biosynthetic Precursors. Lancaster, U.K., MTP, 1987, p. 1-171
48. Markussen J, Damgaard U, Diers I, Fiil N, Hansen MT, Larsen P, Norris F, Norris K, Schou O, Snel L, Thim L, Voigt HO: Biosynthesis of human insulin in yeast via single-chain precursors. In Peptides 1986. Theodoropoulos D, Ed. Berlin, Walter de Gruyter, 1987, p. 189-194
49. Chan SJ, Weiss J, Konrad M, White T, Bahl C, Yu SD, Marks D, Steiner DF: Biosynthesis and periplasmic segregation of human pro insulin in Escherichiacoli. Proc Natl Acad Sci U S A 78:5401-5405, 1981